Post-Operative Pain

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
lyricaPhase 31 trial
Active Trials
NCT01391858Completed80Est. Jun 2013
Heron Therapeutics
1 program
1
Bupivacaine HCI without epinephrinePhase 21 trial
Active Trials
NCT04911062CompletedEst. Aug 2022
Providence Therapeutics
1 program
Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrineN/A1 trial
Active Trials
NCT06008821UnknownEst. Nov 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizerlyrica
Heron TherapeuticsBupivacaine HCI without epinephrine
Providence TherapeuticsBilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine

Clinical Trials (3)

Total enrollment: 80 patients across 3 trials

NCT01391858Pfizerlyrica

Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica

Start: Dec 2006Est. completion: Jun 201380 patients
Phase 3Completed
NCT04911062Heron TherapeuticsBupivacaine HCI without epinephrine

HTX-011 in Spinal Surgery

Start: Apr 2022Est. completion: Aug 2022
Phase 2Completed
NCT06008821Providence TherapeuticsBilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine

Paravertebral Block for Improvement of Quality of Recovery Following Cardiac Surgery

Start: Oct 2023Est. completion: Nov 2025
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space